Quantcast

XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity - Valley News Live - KVLY/KXJB - Fargo/Grand Forks

XTL Bio's hCDR1 Compound Highlighted in Article Reviewing Potential Candidates for the Treatment of Lupus Published in Journal of Autoimmunity

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE XTL Biopharmaceuticals Ltd.

HERZLIYA, Israel, July 16, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, announced today that an overview of its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE) is included in an article titled, Novel Approaches to the Development of Targeted Therapeutic Agents for Systemic Lupus Erythematosus.  The article was written by Zev Sthoeger, Amir Sharabi and Edna Mozes. The article has been published in the Journal of Autoimmunity.  

The article summarizes the information available on the four most actively studied peptides based on their ability to suppress lupus manifestations, which includes pCONS, Nucleosomal Peptides, P140 (LUPUZOR) and hCDR1. The common denominator for these peptides is being tolerogenic T cell epitopes that down-regulate specifically lupus associated autoimmune responses.

"We are extremely pleased that Prof. Mozes' review of our hCDR1 peptide for the treatment of lupus was included in the recent article published in the Journal of Autoimmunity," stated Josh Levine, Chief Executive Officer of XTL. "According to the article, out of the four peptides studied, hCDR1 was identified as one of the synthetic peptides to demonstrate highly beneficial effects in experimental and human SLE trials. As a result, hCDR1 was referred to as one of the few attractive potential candidates for the specific and safe treatment of lupus patients." 

About XTL Biopharmaceuticals Ltd. ("XTL")
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs. XTL is focused on late stage clinical development of drugs for the treatment of lupus, multiple myeloma and schizophrenia.

XTL is a public company traded on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL shares are included in the following indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Bluetech-50.

Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Investor Contacts:
Jeffrey Goldberger / Garth Russell
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1250
Email: jgoldberger@kcsa.com / grussell@kcsa.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
Powered by 

WorldNowAll content © Copyright 2000 - 2014 WorldNow and Valley News Live. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.